# DESCRIPTION

- introduce cardiovascular disease
- limitations of pharmacological approaches
- limitations of hematopoietic stem cells
- limitations of skeletal myoblasts
- potential of embryonic stem cells
- in vitro engineering of ES cell-derived cardiomyocytes
- primate ES cells features
- spontaneous differentiation of ES cells
- need for directed differentiation protocols
- objectives of the present invention
- provide clinical grade cells
- method for differentiating primate ES cells
- use of BMP2 and receptor tyrosine kinase inhibitor
- selection of cardiovascular progenitors using CD15 marker
- define pluripotency
- define iPS cells
- preparation of iPS cells
- preferred embodiment of the invention
- isolation of primate embryonic stem cells
- cell culture methods
- preferred embodiment of BMP2 protein
- preferred embodiment of CD-15 marker
- angiogenic growth factors
- receptor tyrosine kinase inhibitors
- use of SU5402 and SU11248
- synergic effect of RTK inhibitor with BMP2
- treatment with SU5402 and BMP2
- treatment with SU11248 and BMP2
- method for preparing substantially pure population of progenitor cells
- medium for culturing primate ES cells
- feeder cells for primate ES cells
- basic medium for culturing primate ES cells
- culture medium change
- describe cell colony dissociation
- motivate avoiding confluency
- introduce platelet lysate in medium
- specify platelet lysate concentration
- describe benefits of platelet lysate
- outline platelet lysate preparation
- describe PRP composition
- introduce differentiation medium
- specify differentiation conditions
- describe cardiac progenitor cells
- specify cell surface markers
- define substantially purified population
- describe therapeutic applications
- introduce cardiac progenitor cell separation
- describe antibody-based separation
- specify antibody labeling
- describe magnetic bead separation
- introduce kit for cardiac progenitor cell enrichment
- describe kit components
- outline method for proliferating primate ES cells

## MATERIALS AND METHODS FOR EXAMPLES 1-3

- list materials
- describe equipment

### Equipment

- list equipment

### Culture of Primate ES Cells

- describe culture of primate ES cells
- describe passaging of primate ES cells

### Protocol to Direct the Fate and to Differentiate Primate ES Cells Toward a Cardiac Lineage

- treat primate ES cells with BMP2
- generate embryoid bodies
- monitor cardiac differentiation

### Generation and Selection of Cardiovascular Progenitors

- treat primate stem cells with BMP2 and SU5402
- use FACS analysis to select CD15-positive cells
- perform gene expression profile
- analyze phenotypic analysis of CD15-positive cells

### Culture of Primate ES cells in a Clinical Grade Medium

- describe culture of primate ES cells in clinical grade medium

## BOX 1: Cell Passaging

- describe passaging of ORMES cells
- describe passaging of I6 and HUES cells

## BOX 2: RT-PCR and Real Time Quantitative PCR

- describe RT-PCR
- describe real time quantitative PCR

## Example 4

### A) Materials and Methods

- describe RNA extraction
- describe real-time quantitative PCR
- describe data analysis

### B) Culture and Cardiac Commitment of Human Embryonic Stem Cells

- describe culture and cardiac commitment of HES cells

### C) Myocardial Infarction Model

- describe myocardial infarction model

### D) Rats Randomization and Myocardial Cell Injection

- describe rats randomization and myocardial cell injection

### E) Histopathology

- describe histopathology
- describe immunofluorescence

### F) Results

- describe phenotype of undifferentiated I6 and HUES-1 cell lines
- describe cardiac commitment of HES cells
- describe gene induction in HUES-1 cells
- describe gene expression in embryoid bodies
- describe engraftment of cardiac committed cells
- describe immunostaining of cardiomyocytes
- describe histopathology of transplanted hearts

## Example 5

### Generation of CD15+ Cardiovascular Progenitors from Human iPS Cell Line

- generate iPS cells
- sort and characterise CD15+ cells

## Discussion

- introduce cardiomyocyte differentiation
- motivate BMP2 as cardiogenic factor
- discuss BMP2 conservation across species
- describe BMP2 effect on human iPS cells
- explain SU5402 enhancement of BMP2 effect
- discuss FGF2 antagonism of BMP2 signaling
- describe Cerberus as nodal and BMP antagonist
- discuss self-renewal blockage by SU5402
- report no teratoma formation
- discuss cardiac commitment and differentiation
- compare with previous studies
- discuss engraftment patterns and cardiac fate
- describe immature phenotype of HES cell-derived cardiomyocytes
- discuss factors influencing full differentiation
- compare I6 and HUES-1 cell lines
- discuss Cx43 expression and cardiac regeneration

